Current research of Zevalin and Bexxar in the field of radioimmunotherapy / 复旦学报（医学版）

ABSTRACT

Radioimmunotherapy using monoclonal antibodies incorporated with radionuclide has been showed to be an effective agent for refractory non-Hodgkin's lymphoma (NHL). Many anti-CD20 antibodies labeled with radionuclide, such as 90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab tiuxetan (Bexxar), have been reported to be effective for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed NHL. This review summarizes the current advance in clinical trials and studies of Zevalin and Bexxar for the treatment of NHL patients.